Meeting
2019 ASCO Annual Meeting
Pilot integrated biomarker study of VX15/2503 in combination with ipilimumab and/or nivolumab in patients with resectable metastatic melanoma.
Authors
Michael C. Lowe
Department of Surgery, Emory University, Atlanta, GA
Michael C. Lowe , Gregory B. Lesinski , Keith A. Delman , Melinda Lynne Yushak , Elizabeth E. Evans , Terrence Lee Fisher , Ragini Reiney Kudchadkar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT03769155
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS9603)
DOI
10.1200/JCO.2019.37.15_suppl.TPS9603
Abstract #
TPS9603
Poster Bd #
169b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
First Author: Michael C. Lowe
Poster
2023 ASCO Annual Meeting
The validity of a machine learning algorithm in predicting response to immune checkpoint inhibitors in melanoma.
First Author: Faisal Fa'ak
Poster
2022 ASCO Annual Meeting
Neo-adjuvant T-VEC plus nivolumab combination therapy for resectable early-stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: The NIVEC trial.
First Author: Maartje W. Rohaan
Poster
2023 ASCO Annual Meeting
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.
First Author: Lisanne P. Zijlker